QNRX · Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Market Cap
16.14M
52 Wk Range
$3.25 - $23.50
Previous Close
$3.36
Open
$3.31
Volume
11,249
Day Range
$3.18 - $3.64
Enterprise Value
-16.24M
Cash
33.18M
Avg Qtr Burn
-5.77M
Insider Ownership
3.67%
Institutional Own.
55.40%
Qtr Updated
Sep 30th 2026
